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Abstract
Background: Whereas deficiency of the essential nutrient choline is associated with DNA damage
and apoptosis in cell and rodent models, it has not been shown in humans.
Objective: The objective was to ascertain whether lymphocytes from choline-deficient humans had
greater DNA damage and apoptosis than did those from choline-sufficient humans.
Design: Fifty-one men and women aged 18–70 y were fed a diet containing the recommended
adequate intake of choline (control) for 10 d. They then were fed a choline-deficient diet for up to
42 d before repletion with 138–550 mg choline/d. Blood was collected at the end of each phase, and
peripheral lymphocytes were isolated. DNA damage and apoptosis were then assessed by activation
of caspase-3, terminal deoxynucleotide transferase–mediated dUTP nick end-labeling, and single-
cell gel electrophoresis (COMET) assays.
Results: All subjects fed the choline-deficient diet had lymphocyte DNA damage, as assessed by
COMET assay, twice that found when they were fed the control diet. The subjects who developed
organ dysfunction (liver or muscle) when fed the choline-deficient diet had significantly more
apoptotic lymphocytes, as assessed by the activated caspase-3 assay, than when fed the control diet.
Conclusions: A choline-deficient diet increased DNA damage in humans. Subjects in whom these
diets induced liver or muscle dys-function also had higher rates of apoptosis in their peripheral
lymphocytes than did subjects who did not develop organ dysfunction. Assessment of DNA damage
and apoptosis in lymphocytes appears to be a clinically useful measure in humans (such as those
receiving parenteral nutrition) in whom choline deficiency is suspected.
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Choline is a dietary component that is essential to the normal function of all cells (1). It (or its
metabolites) assures the structural integrity and signaling functions of cell membranes; in
addition, it is the major source of methyl groups in the diet (one of choline's metabolites,
betaine, participates in the methylation of homocysteine to form methionine), and it directly
affects cholinergic neurotransmission and the transport of lipids from the liver (1). One of the
functional consequences of dietary choline deficiency in humans is the development of liver
damage (ie, elevated serum aminotransferase concentrations; 2,3) and muscle damage (ie,
elevated serum creatine phosphokinase concentrations; 4). Cultured hepatocytes and myocytes
died by apoptosis when placed in choline-deficient medium (4-7), which may explain why
liver and muscle cells leaked enzymes into blood in choline-deficient humans.
Choline deficiency has also been associated with DNA damage. In choline-deficient
hepatocytes, when compared with cells grown with choline, leakage of reactive oxygen species
from mitochondria was greater (8,9), and these reactive oxygen species react with lipids and
DNA. In choline-deficient rats, lipid peroxides accumulated (10-13), and there was more DNA
adduct formation and DNA damage in hepatocytes (14) and in lymphocytes (15) than in control
rats. This finding has never been shown in humans.
Better biomarkers for assessment of choline status are important for clinical practice in
nutrition. Low plasma choline concentrations occur in up to 84% of the patients who require
total parenteral nutrition [(TPN) 3,16-20], as does liver damage (3,21) and fatty liver (3). In
some patients, the hepatic dysfunction associated with TPN was resolved with choline
supplementation but then returned when standard TPN was reinstituted (3). Low choline status
is also possible in healthy populations. Dietary choline intakes vary enough in healthy women
in the United States (from <300 to >500 mg/d) to significantly influence the risk that a healthy
woman will have a baby with a birth defect (22). Current assessment of choline status in humans
involves assays of choline, betaine, and phosphatidylcholine concentrations in plasma (2), but
it is important to note that measurement of these biomarkers in humans was not sufficient to
predict which subjects would develop organ dysfunction when fed a choline-deficient diet,
because all choline-depleted subjects had low plasma choline and betaine concentrations, yet
only some developed liver or muscle damage (4,23). Although these plasma concentrations
decreased when humans ate a choline-deficient diet, they stabilized after a decrease of 30% to
50%, probably as a result of homeostatic mechanisms (24). Thus, plasma measurements likely
do not accurately reflect tissue concentrations of choline. An alternative functional marker for
choline deficiency is needed in a readily accessible tissue.
In the current study, men and women were fed a diet containing choline for 10 d and then fed
a choline-deficient diet for ≤42 d before repletion with choline. We determined whether DNA
damage and apoptosis increased during the period of choline depletion and whether these
functional effects of choline deficiency were correlated with susceptibility to liver or muscle
damage when the subjects were fed a choline-deficient diet.
SUBJECTS AND METHODS
Study design
Healthy men (n = 31) and women (n = 35) were recruited for the study. Inclusion was contingent
on a good, age-typical health status, as ascertained by physical examination and standard
clinical laboratory tests such as complete blood count, blood chemistries, fasting lipid and liver
function tests, and the presence of no known chronic disease. Twenty-two subjects admitted
to the study had minor elevations in blood lipids that the study physician deemed not to have
clinical significance. Of the originally recruited 66 subjects, 61 completed at least the initial
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phase and the depletion phase. Of that group, 1 subject was excluded because of a 9-kg weight
loss during the study, and 3 subjects were excluded because they did not comply with diet
restrictions; baseline measurements of DNA damage and apoptosis were not performed in 6
subjects. Thus, 51 subjects were included in the analyses. These 20 men and 31 women ranged
in age from 18 to 70 y and had a body mass index (in kg/m2) between 19 and 33, which they
maintained throughout the study. Two of the post-menopausal women were taking hormone
replacement therapy. The race-ethnicity distribution of the participants was white (63%),
African American (27%), Asian (6%), and Native American (4%), which reflected the local
population characteristics of the Raleigh-Durham-Chapel Hill area.
The subjects were admitted to the General Clinical Research Center at the University of North
Carolina at Chapel Hill, where they remained under the supervision of study staff for the
duration of the study. The diets administered to the subjects, which were composed of high-
biologic-value protein (0.8 g/kg), fat (30% of kcal), and carbohydrate (70% of kcal), were
prepared in-house to protocol specifications; they are described in detail elsewhere (25). Total
food intake was adjusted to be isocaloric and to provide adequate intakes of macronutrients
and micronutrients.
Initially, all participants received a diet of normal foods containing 550 mg choline · 70 kg
body wt−1 · d−1, which is the presumed adequate intake (26), and 400 dietary folate equivalents
(DFE)/d. The dietary choline content was confirmed as described previously (25,27), and the
folate content was calculated by using the US Department of Agriculture Nutrient Database
for Standard Reference (release 16; http://www.ars.usda.gov/ba/bhnrc/ndl) and PRONUTRA
software (version 3.1.0.13; ProNutra, Princeton, NJ). After 10 d, the subjects were randomly
assigned to 1 of 2 groups—dietary folate only or dietary folate supplemented with 400 μg folic
acid/d—and then were fed a diet in which the choline content was reduced to <50 mg/d, as
confirmed by analysis of duplicate food portions (27,28). For the rest of the study, all diets
offered to the folate-only group contained 100 DFE/d, whereas the folic acid–supplemented
group received an additional 668 DFE/d (Figure 1). Plasma folate concentrations were
measured by using a microbiological assay with interassay and intraassay CVs of 3.9% and
3.1%, respectively (29). Periodic measurments of urinary choline and betaine concentrations
were used to confirm compliance with the dietary restrictions. Briefly, urine was collected
(pooled for 24 h) at the end of the baseline, depletion, and repletion phases, as well as on days
13 and 31 of the choline-deficient diet. Aliquots were stored at −80 °C until they were analyzed
for choline and betaine by the method of Koc et al (28).
Subjects continued to be fed this choline-depletion diet until they developed organ dysfunction
associated with choline deficiency or for 42 d if they did not develop such dysfunction. Humans
were deemed to have organ dysfunction associated with choline deficiency if their serum
creatine phosphokinase (CPK) activity rose >5-fold from baseline (4) or if liver fat content
increased by >28% during the choline-depletion diet, and if this greater CPK activity or higher
liver fat content resolved when choline was restored to the diet. After the depletion study,
subjects with no dysfunction were maintained on a diet containing 550 mg choline/d for ≥3 d
before being discharged from the study. Those with organ dysfunction underwent choline
repletion by receiving 137.5 mg choline · 70 kg−1 · d−1 (25% adequate intake) for 10 d and
then 275, 412.5, and 550 mg choline · 70 kg−1 · d−1 in successive 10-d periods. At the point
when the clinical symptoms were resolved, the subjects were fed >550 mg choline · 70 kg−1 ·
d−1 ≥3d.
Written informed consent was obtained from all participants. The study protocol was approved
by the Institutional Review Board at the University of North Carolina at Chapel Hill.
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Assessment of fatty liver
Liver fat was measured at the end of the baseline diet, on days 21 and 42 of the choline-deficient
diet, and at the end of the repletion period (for subjects with fatty liver when fed the choline-
deficient diet). Change in liver fat content was estimated by magnetic resonance imaging with
a Siemens Vision 41.5T clinical MR system (Siemens Medical Solutions, Malvern, PA) using
a modified “In and Out of Phase” procedure (23,30). This approach uses the differences in
transverse magnetization intensity after a fast low-angle shot [(FLASH) echo time = 2.2 and
4.5 msec, with a flip angle of 80°, and repetition time = 140 msec]. Processing of successive
FLASH magnetic resonance images with the software from Siemens Medical Solutions was
used to estimate fat content. Organ content was derived from measurements across 3–5 liver
slices per subject and standardized by relating the results to similarly measured slices of spleen.
Assessment of liver and muscle cell damage
Fasting blood samples were taken every 3–4 d for blood chemistry analyses (including CPK
analysis). For the lymphocyte studies, they were also obtained after 10 d of the baseline diet,
at the end of the choline-deficient diet (depletion phase), and at the end of the choline-repletion
phase. Absolute lymphocyte counts were performed on an Advia analyzer (Bayer, Tarrytown,
NY). Serum was analyzed by using a dry-slide colorimetric method for CPK activity
[McClendon Clinical Laboratories, University of North Carolina Hospitals, Chapel Hill, NC,
which are accredited by both the Clinical Laboratory Improvement Act (CLIA) and the College
of American Pathologists].
Assessment of lymphocyte DNA damage and apoptosis
Peripheral lymphocytes were isolated from blood by using Ficoll-Hypaque gradient in
evacuated tubes with sodium citrate (Vacutainer CPT; Becton Dickinson, Franklin Lakes, NJ)
according to the manufacturer's instructions (31,32). DNA was measured by using the method
of Labarca and Paigen (33). The cells were then analyzed by using the ApoTarget Caspase-3/
CPP32 Colorimetric Protease Assay (BioSource International, Camarillo, CA). Briefly,
activated caspase-3 cleaves the 4-nitroaniline peptide substrate DEVD-pNA, and this activity
is quantified at 405-nm absorbance by using ultraviolet spectrometry and expressed as
integrated optical density/mg DNA. Activated caspase-3 was also measured in a subset of cells
by labeling them with carboxyfluorescein (FAM)-labeled peptide fluoromethyl ketone (FMK)
caspase inhibitor (FAM-DEVD-FMK, CaspaTag kit; Intergen, Purchase, NY), which
specifically binds to activated caspase-3. Nuclei were then stained with 4′-6-diamidino-2-
phenylindole, and activated caspase-3 was detected by using a band-pass filter (excitation
wavelength: 490 nm; emission wavelength: 520 nm) on a microscope. We used an ultraviolet
filter (excitation wavelength: 365 nm; emission wavelength: 4600 nm) to visualize the nuclear
staining, and the National Institutes of Health–based SCION IMAGE software (version 4.03;
Scion Corporation, Frederick, MD) to quantify the activated caspase-3–integrated absorption.
We measured DNA fragmentation in lymphocytes by using terminal deoxynucleotidyl
transferase–mediated dUTP nick end-labeling [(TUNEL) ApopTag Plus in Situ Apoptosis
Detection Kit; Chemicon International, Temecula, CA]. Lymphocytes were fixed in 2%
paraformaldehyde and suspended on a silanized microscope slide by cytospin. They were
labeled and stained with diaminobenzidine-peroxidase, and the nuclei were counterstained with
0.5% methyl green. The slides were mounted, and the TUNEL-positive cells were counted by
light microscopy. At least 300 total cells were counted for each data point, and the amount is
expressed as a percentage.
We assessed DNA strand breaks by using single-cell gel electrophoresis (COMET assay; 34).
Lymphocytes were sandwiched between 0.5% agarose and 0.5% low-melting-point (37 °C)
agarose (Fisher, Fair Lawn, NJ). The resulting slides were placed into cold, freshly made lysis
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solution [10 mmol Tris/L (pH 10), 2.5 mol NaCl/L, 100 mmol EDTA/L, 1% sodium
sarcosinate, 10% DMSO, and 1% Triton X-100] at 4 °C for ≥1 h and then treated for 20 min
in electrophoresis buffer [300 mmol NaOH/L, 1 mmol EDTA/L (pH 13)]. After electrophoresis
was performed at 25 V and 300 mA for 20 min, slides were incubated 3 times for 5 min in
neutralization buffer [0.4 mol Tris/L (pH 7.5)], washed with methanol, and stained with 20 mg
ethidium bromide/mL. COMET tail length (the distance of DNA migration from the body of
the nuclear core) was visualized by using a fluorescence microscope (typically, 100 cells/
sample) and SCION IMAGE software. The COMET tail moment (defined as the integrated
density in the COMET tail multiplied by the distance from the center of the nucleus to the
center of mass of the tail) was calculated by using the NIH IMAGE ANALYSIS MACRO
language software (http://dir.nhlbi.nih.gov/labs/ldn/macroanalysis.asp).
Statistical analysis
Significant differences in urinary data between subjects after they consumed the baseline (550
mg choline/d) diet and the same subjects after they consumed the choline-deficient and choline-
repletion diets were determined by analysis of variance (ANOVA) and Dunnett's test. A 2-
factor analysis with interaction based on the differences between the activated caspase-3,
TUNEL, and COMET measurements; the lymphocyte counts; and plasma folate concentrations
at the end of the baseline and choline-deficient diets was used to determine significant
interactions between organ dysfunction and folate status. The interactions were not significant,
so a 2-factor ANOVA was then used to compare these groups. A 2-sample t test based on the
differences between the lymphocyte counts and activated caspase-3, TUNEL, COMET, and
plasma folate measurements at the end of the baseline and choline-repletion diets for the folate-
only and the folic acid–supplemented groups was performed to determine whether folate had
an effect on these measurements. If folate had no effect, paired t tests were then used to compare
measurements between the baseline and repletion diets. Statistical analysis was performed by
using JMP software (version 3.2; SAS Institute Inc, Cary, NC).
RESULTS
Organ dysfunction
Thirty-three (65%) of 51 subjects developed organ dysfunction when fed the choline-deficient
diet. Of this group, 26 (8 men and 18 women) had liver dysfunction, 1 (a man) had only muscle
dysfunction, and 6 (5 men and 1 woman) had both liver and muscle dysfunction. All subjects
returned to normal with choline repletion. Urinary betaine and choline concentrations dropped
to 60% of baseline after subjects consumed the choline-deficient diet for 13 d (Figure 2) and
were <50% of baseline at the end of the depletion period (P < 0.01, ANOVA and Dunnett's
test). When choline was restored to the diet (for 3 d in those with no clinical symptoms and for
>3 d in those with symptoms), urinary concentrations of both metabolites increased to >80%
of baseline (Figure 2).
Lymphocyte counts
Mean total lymphocyte counts at the end of the choline-depletion period (2.3±0.1×106/mL)
did not differ significantly from baseline values, regardless of organ dysfunction or folate status
(Table 1). Lymphocyte counts in the subjects at the end of the repletion diets (2.2 ±0.1 ×106/
mL) also did not differ significantly from baseline values (P = 0.479, paired t test).
Activated caspase-3 assay
The amount of activated caspase-3 in the lymphocytes of subjects who developed organ
dysfunction after they were fed a low choline-diet was significantly greater than their baseline
values (P = 0.018 by 2-factor ANOVA; Table 1). Subjects who did not develop organ
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dysfunction had no increase in mean activated caspase-3 in their lymphocytes. The effect of
the choline-deficient diet was not changed by supplementation with folic acid (Table 1). When
choline was restored to the diet of the subjects with organ dysfunction, activated caspase-3
returned to 104 ± 21% of baseline (P = 0.842 for difference from baseline, paired t test; n =
27).
TUNEL assay
There were more TUNEL-positive lymphocytes in subjects at the end of the choline-depletion
period than when they were fed the baseline diet (Table 1). There was no significant interaction
between liver-muscle dysfunction and folate status, but subjects who were not supplemented
with folic acid had significantly (P = 0.026) more TUNEL-positive cells than did subjects
receiving the supplement. When choline was restored to the diet of the subjects with organ
dysfunction, there was a partial reduction in the proportion of TUNEL-positive lymphocytes
(to 2.4 ± 0.4%; P = 0.034 for difference from baseline values, paired t test; n = 23); there was
no effect of folate status on the postrepletion TUNEL assay values (P = 0.940, t test).
COMET assay
At the end of the choline-depletion period, we observed that all subjects, regardless of whether
they became sufficiently choline-depleted to develop liver or muscle dysfunction, had
lymphocyte DNA damage (assessed by the COMET assay) twice that seen when they were
fed the control diet (Table 1). This increase in tail moment occurred regardless of whether
subjects also developed other signs of organ dysfunction when fed the choline-deficient diet
and was independent of dietary folate intake. At the end of the choline-repletion period, when
all choline deficiency–associated organ dysfunction had resolved, the average COMET tail
moment in the lymphocytes of subjects was 1.2 ± 0.1 (P = 0.428 for difference from baseline,
paired t test; n = 27).
Folate assay
At the end of the baseline diet period, mean plasma folate concentrations in the subjects were
26.0 ± 0.9 nmol/L (Table 1), which was within the range of values reported for humans
consuming 427 μg folate/d (35). When subjects were fed the choline-deficient diet
supplemented with folic acid, the mean plasma folate concentration was 27.8 ± 1.3 nmol/L
(P = 0.038 for difference from baseline, paired t test; n = 26). When these subjects underwent
repletion with added choline, the mean plasma folate concentration did not change (28.2 ± 1.9
nmol/L). When subjects were fed the choline-deficient diet and did not receive folic acid (100
DFE/d from diet alone), mean plasma folate concentrations decreased to 21.4 ± 1.3 nmol/L
(P = 0.0003 for difference from the supplemented group, 2-factor ANOVA). This value is still
well above that which indicates folate deficiency (7 nmol/L; 36). In these subjects at the end
of the choline-repletion period, the mean plasma folate concentration (26.2 ± 1.6 nmol/L) did
not differ from baseline.
DISCUSSION
We found that choline deficiency in humans was associated with significant damage to DNA
and with apoptosis in peripheral lymphocytes. This association had not previously been shown
in humans.
Caspase-3 is a critical effector protein in apoptosis, and it exists within the cytosol as an inactive
dimer (37). Cleavage within a linker segment is required for activation, which occurs only
during the terminal execution cascade of signals mediating apoptosis (37). Thus, activated
caspase-3 is an extremely specific marker for apoptosis. We observed that activated caspase-3
increased in the lymphocytes of subjects who developed organ dysfunction when fed a choline-
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deficient diet (Table 1). TUNEL labeling is often cited as a specific biomarker for apoptosis
because the technique identifies cells with single-strand nicks in DNA. However, the assay
also detects nonapoptotic events that result in DNA damage (38,39). Our data are consistent
with this finding, because our TUNEL assay values appear to be intermediate between activated
caspase-3 values, which increased only in subjects who developed organ dysfunction when fed
a choline-deficient diet, and COMET tail moment values, which increased in all subjects fed
a choline-deficient diet. The COMET assay measures double-strand breaks in DNA (34) as
well as DNA modifications such as abasic sites (AP sites) (40). This assay is different from
both the TUNEL assay, which detects single- and double-strand breaks in DNA, and the
activated caspase-3 assay, which detects specific activation of the apoptotic signaling cascade
that is responsible for cell execution (41). Whether DNA lesions detected by the COMET assay
go on to become gene mutations depends on whether they are correctly repaired without
resulting in permanent genetic alterations (40).
As noted earlier, in animal models, choline deficiency increased leakage of reactive oxygen
species from mitochondria (8,9) and increased DNA adduct formation and DNA damage in
liver (14,15). In the current study, we observed that all subjects, as compared with the values
when they were fed the control diet, had twice as much lymphocyte DNA damage (COMET
assay) when they were fed the choline-deficient diet, even if choline was not sufficiently
depleted to lead to liver or muscle dysfunction (Table 1). No evidence exists of a mechanism
for choline interactions with DNA that is particular to lymphocytes, rather than to other tissues,
and thus it is likely that damage to DNA is not organ specific. Perhaps damage to DNA is the
earliest functional effect of choline deficiency and occurs before intracellular concentrations
of choline or phosphatidylcholine decrease enough to induce apoptosis and leakage of enzymes
from liver and muscle or fatty liver. If so, increased DNA damage as assessed by COMET
assays could be the earliest marker for identification of a tissue as choline-deficient.
We suggest that choline deficiency–induced apoptosis shares a mechanism with other measures
of organ dysfunction associated with choline deficiency—ie, diminished synthesis of
phosphatidylcholine. Fatty liver occurs in choline deficiency because phosphatidylcholine is
not available for secretion of VLDL from liver (42). Muscle dysfunction in choline deficiency
likely occurs because lower membrane phosphatidylcholine concentrations make myocytes
fragile (4). We previously reported that membrane phosphatidylcholine concentrations may be
the critical variable for choline deficiency–mediated induction of apoptotic cascades (9,43).
Choline and folate metabolisms are interrelated (1), and it has been suggested that folate status
can modify susceptibility to choline deficiency (44). In the current study, the changes in plasma
folate were modest, although they did occur in the direction we expected. It is possible that the
experimental period in the current study—which was as short as 2 wk and as long as 6 wk—
was not long enough for the dietary changes (from 400 to 100 or 768 DFE) to reach a plateau
in plasma folate; it has been reported that 6–14 wk is required for that outcome (45). It could
have been predicted that humans ingesting a choline-deficient diet containing 100 DFE/d would
have decreased plasma folate concentrations because this folate intake is less than that
estimated for humans eating an ad libitum diet (≈200 DFE/d from naturally occurring food
folate, in addition to the contribution from foods fortified with folic acid) (46). We present
folate data to show that our subjects did not become frankly folate deficient (plasma folate
concentrations were well above those indicative of folate deficiency; 36). Supplementary folic
acid mitigated some but not all of the effects of the choline-deficient diet on increasing TUNEL
labeling but did not mitigate choline deficiency–associated changes in activated caspase-3 or
in COMET tail moment. The restoration to the diet of choline, without restoration of folate,
returned COMET and activated caspase-3 values to normal. Thus, choline deficiency and not
diminished folate status was responsible for the changes that we report here.
da Costa et al. Page 7













That choline deficiency induces significant DNA damage in humans is an important
observation. In rodent models, prolonged (ie, 1 y) choline deficiency results in the development
of liver cancers (47) and in greater sensitivity to chemical carcinogens (48). These conditions
could be the result of mutations due to DNA damage. Similarly, choline deficiency–induced
apoptosis is of clinical significance, because liver damage is a common side effect of prolonged
parenteral nutrition (16). At present, there is no definitive clinical test that can be used to
identify persons who are choline deficient. Plasma choline, betaine, and phosphatidylcholine
concentrations decreased in humans fed a choline-deficient diet, but they plateau after falling
30%–50% (2,24). Urinary betaine and choline concentrations also decreased in humans
consuming a choline-deficient diet, and we used that measure as a compliance marker in this
study. Lower concentrations of choline metabolites are necessary but not sufficient to predict
who will develop organ dysfunction (4,23). In the current study, we identified a number of
biomarkers that can be used in conjunction with plasma choline metabolites to make a diagnosis
of choline deficiency in humans. COMET tail moment may be the most sensitive measure, and
dose-response studies should be performed to ascertain the exact dietary intake at which
COMET values become abnormal. Activated caspase-3 measurements in lymphocytes
correlated best with liver and muscle dysfunction that was associated with choline deficiency.
Thus, this assessment has clinical value for physicians who might use it as an indicator for
ordering studies of liver or muscle function in patients suspected of being choline deficient.
The TUNEL assay was influenced by folate status as well as by choline status, and thus it is
not as specific a biomarker for choline deficiency as are the other assays.
The human dietary requirement for an essential nutrient is defined as the amount that prevents
organ dysfunction. The Institute of Medicine Dietary Reference Intake Panel defined the
human requirement for choline according to the amount of dietary intake needed to prevent
liver dysfunction (ie, elevated serum transaminase concentrations; 26). Because apoptosis and
DNA damage in lymphocytes are measures of significantly abnormal cell function, we suggest
that these measures in a clinically accessible tissue could be used to define the human dietary
requirement for choline.
Acknowledgements
We thank Mihaela Badea for help with the caspase assays and Lester Kwock for assistance with MRI measurements.
KD participated in the design of the studies, supervised blood collection and processing and the caspase assays,
participated in statistical analyses and data interpretation, and participated in writing the manuscript. MDN performed
the TUNEL analyses, and CC performed the COMET assays; both participated in writing the manuscript. LMF
participated in the supervision of the human study. SHZ was responsible for the conceptualization, implementation,
and design of the human study; participated in statistical analyses and data interpretation; and participated in writing
the manuscript. SHZ receives grant support from Mead Johnson for studies other than those described here and serves
on an advisory board for the Solae Company.
REFERENCES
1. Zeisel SH, Blusztajn JK. Choline and human nutrition. Annu Rev Nutr 1994;14:269–96. [PubMed:
7946521]
2. Zeisel SH, da Costa K-A, Franklin PD, et al. Choline, an essential nutrient for humans. FASEB J
1991;5:2093–8. [PubMed: 2010061]
3. Buchman AL, Ament ME, Sohel M, et al. Choline deficiency causes reversible hepatic abnormalities
in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled
trial. JPEN J Parenter Enteral Nutr 2001;25:260–8. [PubMed: 11531217]
4. da Costa KA, Badea M, Fischer LM, Zeisel SH. Elevated serum creatine phosphokinase in choline-
deficient humans: mechanistic studies in C2C12 mouse myoblasts. Am J Clin Nutr 2004;80:163–70.
[PubMed: 15213044]
da Costa et al. Page 8













5. Albright CD, Lui R, Bethea TC, da Costa K-A, Salganik RI, Zeisel SH. Choline deficiency induces
apoptosis in SV40-immortalized CWSV-1 rat hepatocytes in culture. FASEB J 1996;10:510–6.
[PubMed: 8647350]
6. Albright CD, da Costa KA, Craciunescu CN, Klem E, Mar MH, Zeisel SH. Regulation of choline
deficiency apoptosis by epidermal growth factor in CWSV-1 rat hepatocytes. Cell Physiol Biochem
2005;15:59–68. [PubMed: 15665516]
7. Albright CD, Salganik RI, Kaufmann WK, Vrablic AS, Zeisel SH. A p53-dependent G1 checkpoint
function is not required for induction of apoptosis by acute choline deficiency in immortalized rat
hepatocytes in culture. J Nutr Biochem 1998;9:476–81.
8. Albright CD, Salganik RI, Craciunescu CN, Mar MH, Zeisel SH. Mitochondrial and microsomal
derived reactive oxygen species mediate apoptosis induced by transforming growth factor-beta1 in
immortalized rat hepatocytes. J Cell Biochem 2003;89:254–61. [PubMed: 12704789]
9. Vrablic AS, Albright CD, Craciunescu CN, Salganik RI, Zeisel SH. Altered mitochondrial function
and overgeneration of reactive oxygen species precede the induction of apoptosis by 1-O-octadecyl-2-
methyl-rac-glycero-3-phosphocholine in p53-defective hepatocytes. FASEB J 2001;15:1739–44.
[PubMed: 11481221]
10. Rushmore T, Lim Y, Farber E, Ghoshal A. Rapid lipid peroxidation in the nuclear fraction of rat liver
induced by a diet deficient in choline and methionine. Cancer Lett 1984;24:251–5. [PubMed:
6498804]
11. Yoshida LS, Miyazawa T, Fujimoto K, Kaneda T. Liver phosphatidylcholine hydroperoxidation
provoked by ethionine-containing choline-deficient diet in mice. Lipids 1990;25:565–9. [PubMed:
2250595]
12. Ghoshal AK, Farber E. Liver biochemical pathology of choline deficiency and of methyl group
deficiency: a new orientation and assessment. Histol Histopathol 1995;10:457–62. [PubMed:
7599441]
13. Banni S, Corongiu FP, Dessi MA, et al. Free radicals and lipid peroxidation in liver of rats kept on a
diet devoid of choline. Free Radic Res Commun 1989;7:233–40. [PubMed: 2555277]
14. Pogribny IP, Basnakian AG, Miller BJ, Lopatina NG, Poirier LA, James SJ. Breaks in genomic DNA
and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats.
Cancer Res 1995;55:1894–901. [PubMed: 7794383]
15. James SJ, Yin L. Diet-induced DNA damage and altered nucleotide metabolism in lymphocytes from
methyl-donor-deficient rats. Carcino-genesis 1989;10:1209–14.
16. Buchman A, Dubin M, Moukarzel A, et al. Choline deficiency: a cause of hepatic steatosis during
parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology
1995;22:1399–403. [PubMed: 7590654]
17. Buchman AL, Moukarzel A, Jenden DJ, Roch M, Rice K, Ament ME. Low plasma free choline is
prevalent in patients receiving long term parenteral nutrition and is associated with hepatic
aminotransferase abnormalities. Clin Nutr 1993;12:33–7. [PubMed: 16843274]
18. Burt ME, Hanin I, Brennan MF. Choline deficiency associated with total parenteral nutrition. Lancet
1980;2:638–9. [PubMed: 6107423]
19. Sheard NF, Tayek JA, Bistrian BR, Blackburn GL, Zeisel SH. Plasma choline concentration in humans
fed parenterally. Am J Clin Nutr 1986;43:219–24. [PubMed: 3080867]
20. Shronts EP. Essential nature of choline with implications for total parenteral nutrition. J Am Diet
Assoc 1997;97:639–46. [PubMed: 9183326]649
21. Tayek JA, Bistrian B, Sheard NF, Zeisel SH, Blackburn GL. Abnormal liver function in malnourished
patients receiving total parenteral nutrition: a prospective randomized study. J Am Coll Nutr
1990;9:76–83. [PubMed: 2106545]
22. Shaw GM, Carmichael SL, Yang W, Selvin S, Schaffer DM. Periconceptional dietary intake of choline
and betaine and neural tube defects in offspring. Am J Epidemiol 2004;160:102–9. [PubMed:
15234930]
23. da Costa KA, Gaffney CE, Fischer LM, Zeisel SH. Choline deficiency in mice and humans is
associated with increased plasma homocysteine concentration after a methionine load. Am J Clin
Nutr 2005;81:440–4. [PubMed: 15699233]
da Costa et al. Page 9













24. Savendahl L, Mar M-H, Underwood L, Zeisel S. Prolonged fasting results in diminished plasma
choline concentration but does not cause liver dysfunction. Am J Clin Nutr 1997;66:622–5. [PubMed:
9280183]
25. Busby MG, Fischer L, Da Costa KA, Thompson D, Mar MH, Zeisel SH. Choline- and betaine-defined
diets for use in clinical research and for the management of trimethylaminuria. J Am Diet Assoc
2004;104:1836–45. [PubMed: 15565078]
26. Institute of Medicine, National Academy of Sciences. Dietary reference intakes for folate, thiamin,
riboflavin, niacin, vitamin B12, panthothenic acid, biotin, and choline. National Academy Press;
Washington, DC: 1998. Choline; p. 390-422.
27. Zeisel SH, Mar MH, Howe JC, Holden JM. Concentrations of choline-containing compounds and
betaine in common foods. J Nutr 2003;133:1302–7. [PubMed: 12730414]
28. Koc H, Mar MH, Ranasinghe A, Swenberg JA, Zeisel SH. Quantitation of choline and its metabolites
in tissues and foods by liquid chromatography/electrospray ionization-isotope dilution mass
spectrometry. Anal Chem 2002;74:4734–40. [PubMed: 12349977]
29. Horne DW, Patterson D. Lactobacillus casei microbiological assay of folic acid derivatives in 96-
well microtiter plates. Clin Chem 1988;34:2357–9. [PubMed: 3141087]
30. Fishbein M, Gardner K, Potter C, Schmalbrock P, Smith M. Introduction of fast MR imaging in the
assessment of hepatic steatosis. Magn Reson Imaging 1997;15:287–93. [PubMed: 9201675]
31. Fotino M, Merson E, Allen F. Micromethod for rapid separation of lymphocytes from peripheral
blood. Ann Clin Lab Sci 1971;1:131–3. [PubMed: 5154596]
32. Ting A, Morris P. A technique for lymphocyte preparation from stored heparinized blood. Vox Sang
1971:561–3. [PubMed: 5098546]
33. Labarca C, Paigen K. A simple, rapid and sensitive DNA assay procedure. Anal Biochem
1980;102:344–52. [PubMed: 6158890]
34. Sauvaigo S, Serres C, Signorini N, Emonet N, Richard MJ, Cadet J. Use of the single-cell gel
electrophoresis assay for the immunofluorescent detection of specific DNA damage. Anal Biochem
1998;259:1–7. [PubMed: 9606136]
35. Hertrampf E, Cortes F, Erickson JD, et al. Consumption of folic acid-fortified bread improves folate
status in women of reproductive age in Chile. J Nutr 2003;133:3166–9. [PubMed: 14519804]
36. Institute of Medicine, National Academy of Sciences. Dietary reference intakes for folate, thiamin,
riboflavin, niacin, vitamin B12, panthothenic acid, biotin, and choline. National Academy Press;
Washington, DC: 1998. Folate; p. 196-305.
37. Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr Opin Cell Biol 2003;15:725–
31. [PubMed: 14644197]
38. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R. In
situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis,
and autolytic cell death: a cautionary note. Hepatology 1995;21:1465–8. [PubMed: 7737654]
39. Cervos-Navarro J, Schubert T. Pitfalls in the evaluation of apoptosis using TUNEL. Brain Pathol
1996;6:347–8. [PubMed: 8864289]
40. Brendler-Schwaab S, Hartmann A, Pfuhler S, Speit G. The in vivo comet assay: use and status in
genotoxicity testing. Mutagenesis 2005;20:245–54. [PubMed: 15899933]
41. Roser S, Pool-Zobel BL, Rechkemmer G. Contribution of apoptosis to responses in the comet assay.
Mutat Res 2001;497:169–75. [PubMed: 11525920]
42. Yao ZM, Vance DE. The active synthesis of phosphatidylcholine is required for very low density
lipoprotein secretion from rat hepatocytes. J Biol Chem 1988;263:2998–3004. [PubMed: 3343237]
43. Yen CL, Mar MH, Zeisel SH. Choline deficiency-induced apoptosis in PC12 cells is associated with
diminished membrane phosphatidylcholine and sphingomyelin, accumulation of ceramide and
diacylglycerol, and activation of a caspase. FASEB J 1999;13:135–42. [PubMed: 9872938]
44. Jacob RA, Jenden DJ, Allman-Farinelli MA, Swendseid ME. Folate nutriture alters choline status of
women and men fed low choline diets. J Nutr 1999;129:712–7. [PubMed: 10082779]
45. Quinlivan EP, Gregory JF 3rd. Effect of food fortification on folic acid intake in the United States.
Am J Clin Nutr 2003;77:221–5. [PubMed: 12499345]
da Costa et al. Page 10













46. Choumenkovitch SF, Selhub J, Wilson PW, Rader JI, Rosenberg IH, Jacques PF. Folic acid intake
from fortification in United States exceeds predictions. J Nutr 2002;132:2792–8. [PubMed:
12221247]
47. Newberne PM, Rogers AE. Labile methyl groups and the promotion of cancer. Annu Rev Nutr
1986;6:407–32. [PubMed: 2425831]
48. Rogers AE, Akhtar R, Zeisel SH. Procarbazine carcinogenicity in methotrexate-treated or lipotrope-
deficient male rats. Carcinogenesis 1990;11:1491–5. [PubMed: 2401040]
da Costa et al. Page 11














Overview of study design. The choline content of the baseline, depletion, and repletion phases
is indicated. Subjects who developed organ dysfunction when fed the choline-deficient diet
underwent repletion with graded increasing concentrations of choline for 10 d each until signs
of organ dysfunction resolved [137.5 (25%), 275 (50%), 412.5 (75%), and finally 550 mg
choline · 70 kg−1 · d−1 (100%)]. The baseline diet provided 400 dietary folate equivalents
(DFE)/d. The choline-depletion and -repletion diets provided 100 DFE/d. On day 11, subjects
were randomly assigned to receive placebo (100 DFE/d) or 400 μg folic acid supplement/d for
the remainder of the study.
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Mean (±SE) urinary betaine and choline concentrations (n = 32–45/time point), from which
dietary compliance was assessed. Subjects were treated as described in the legend for Figure
1. Urine samples (24-h) were collected at the end of the baseline (550 mg), depletion (Depl),
and repletion (Repl) phases and on days 13 and 31 of the choline-deficient diet (D13CD and
D31CD, respectively), and aliquots were analyzed for betaine ( ) and choline (□)
concentrations nmol/mg creatinine as described in Methods. *Significantly different from
baseline, P < 0.01 (one-factor ANOVA and Dunnett's test).
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